Brutal Underpriced Gem..
Redhill Biopharma (RDHL)
Market Cap: $60 M
Cash: $14.7 M
Burn-rate : ~$10 per Year
Shares Out: 6.3 M ( Management holds over 2.6 M shares )
Float: 4 M
RHB-103 - An oral thin film formulation of rizatriptan, for the treatment of acute migraine, with a U.S. NDA filed and accepted for review by the FDA and a PDUFA date of February 3, 2014.Market Size: Worldwide triptan market for the treatment of migraine exceeds $2 billion*
RHB-102 - A once-daily formulation of ondansetron, for the treatment of chemotherapy and radiotherapy-induced nausea and vomiting, planned for U.S. NDA submission during the first quarter of 2014.Market Size: Worldwide market for serotonin (5-HT3) receptor inhibitors is estimated at $900 million**
RHB-101 - A once-daily formulation of carvedilol, for the treatment of congestive heart failure and high blood pressure, planned to be submitted for a U.S. New Drug Application (NDA) and a Marketing Authorization Application (MAA) in Europe during the second half of 2014.Market Size: Worldwide target market of $500 million**
RHB-105 - A combination therapy for Helicobacter pylori infection, planned to commence a phase II/III trial in the third quarter of 2013.Market Size: U.S. market is estimated at approximately $1-1.5 billion*
RHB-104 - A combination therapy for the treatment of Crohn’s disease, with a phase III clinical study underway.Market Size: Worldwide market exceeded $3.5 billion in 2012
RHB-104 - A combination therapy for the treatment of Multiple Sclerosis (MS), with a Phase IIa proof of concept trial currently underway.Market Size: Worldwide market of over $14 billion*
RHB-104 - A combination therapy for the treatment of Rheumatoid Arthritis, with a planned Phase IIa study.Market Size: Worldwide market of over $20 billion*
RHB-106 - An encapsulated formulation for bowel preparation (laxative) ahead of colonoscopy and other GI procedures.Market Size: Worldwide market is estimated at approximately $1.4 billion
This Low Float Rocket will hit $6++ before FDA decision on October 17 ...PSDV will move into double digits easily with FDA approval for Blockbuster Candidate Iluven .There is NO FDA approved drugs for DME (Diabetic Macular Edema) .
Upon US approval of Iluvien, pSivida would be entitled to receive a $25 million milestone payment from Alimera and 20 percent of net profits, as defined, on sales of the drug by Alimera.
DME is a potentially blinding disease that affects over one million people in the United States. Currently there are no FDA approved drugs for the treatment of DME.The U.S. market for DME is $1.5 billion to $4 billion.
Pfizer is third largest Shareholder of PSDV holding 1.9 M Shares . PSDV is very close to profitability .
Market Cap: $90 M
Cash: $21 M
Shares Out: 26.8 M ( 10.4 M shares held by Insiders & Institutions)
“We are very pleased that the FDA has accepted Alimera Sciences’ recently resubmitted New Drug Application for ILUVIEN® for chronic Diabetic Macular Edema (DME) and has set a PDUFA target date of October 17, 2013." Upon US approval of Iluvien, pSivida would be entitled to receive a $25 million milestone payment from Alimera and 20 percent of net profits, as defined, on sales of the drug by Alimera.
The injectable, sustained release micro-insert ILUVIEN® for the treatment of chronic DME considered insufficiently responsive to available therapies, licensed to Alimera Sciences, Inc., has received marketing authorization in Austria, France, Germany, Portugal, Spain and the U.K. and is awaiting authorization in Italy.